文献速递神经免疫神经肌肉病

重症肌无力治疗疗效与安全性的贝叶斯网络荟萃分析

Comparison of the Efficacy and Safety of Myasthenia Gravis Treatments: A Bayesian Network Meta-Analysis.
PubMed 文献 · Neurology · 2026-07-17

该贝叶斯网络荟萃分析纳入27项安慰剂对照随机试验,比较FcRn抑制剂、C5补体抑制剂和CD19+ B细胞清除疗法等对全身型重症肌无力的疗效。结果显示三类疗法在QMG和MG-ADL评分改善上无显著差异,但FcRn抑制剂治疗相关不良事件风险更高。

要点

  • FcRn抑制剂、C5抑制剂和CD19+ B细胞清除疗法疗效相当
  • FcRn抑制剂治疗相关不良事件风险较安慰剂增高
  • 试验人群差异可能混淆疗效比较,需前瞻性对比研究

核心结论

  • FcRn抑制剂、C5抑制剂和CD19+ B细胞清除疗法在QMG和MG-ADL改善上疗效相当,未观察到有意义的组间差异。

研究设计与样本

  • 贝叶斯网络荟萃分析,检索5个数据库至2025年5月2日,纳入27项安慰剂对照随机试验,安慰剂组1086例、治疗组1232例。

主要发现

  • 与安慰剂加标准治疗相比,FcRn抑制剂组QMG评分平均多降低3.63分(95%可信区间-4.43至-2.77)。
  • C5补体抑制剂组QMG评分平均多降低2.59分(95%可信区间-3.92至-1.28)。
  • CD19+ B细胞清除疗法组QMG评分平均多降低2.50分(95%可信区间-5.11至0.12)。
  • MG-ADL治疗效应:FcRn抑制剂-1.93(-2.21至-1.65),C5抑制剂-1.84(-2.48至-1.19),CD19+ B细胞清除疗法-1.91(-2.97至-0.84)。
  • FcRn抑制剂组治疗相关不良事件比值比为2.20(1.52-3.38),C5抑制剂和CD19+ B细胞清除疗法与安慰剂相当。

关键数值与推荐

  • FcRn抑制剂QMG改善-3.63分(95%可信区间-4.43至-2.77),MG-ADL改善-1.93分(-2.21至-1.65)。
  • C5补体抑制剂QMG改善-2.59分(95%可信区间-3.92至-1.28),MG-ADL改善-1.84分(-2.48至-1.19)。
  • CD19+ B细胞清除疗法QMG改善-2.50分(95%可信区间-5.11至0.12),MG-ADL改善-1.91分(-2.97至-0.84)。
  • FcRn抑制剂治疗相关不良事件比值比2.20(95%可信区间1.52-3.38)。

临床怎么用

  • 临床选择FcRn抑制剂、C5抑制剂或CD19+ B细胞清除疗法时,可考虑三者疗效相当,但需关注FcRn抑制剂的不良事件风险。

局限性

  • 敏感性分析提示年龄和性别可能混淆治疗效应。
  • 缺乏前瞻性头对头比较研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: In the past decade, several novel therapies have shown promise in treating generalized myasthenia gravis (MG); however, no head-to-head prospective studies have compared their efficacy and safety. To assist clinicians in navigating this complex treatment landscape, we sought to compare treatments while accounting for differences in trial populations. METHODS: We conducted a Bayesian network meta-analysis (PROSPERO ID: CRD42023428733) of MG treatments. We searched Scopus, Embase, Web of Science, CENTRAL, and MEDLINE up to May 2, 2025, for randomized trials in MG. Two independent reviewers (N.M. and M.R.) identified prospective multiarm studies of adults (18 or older) with generalized MG that reported mean treatment difference, with uncertainty, in MG-Activities of Daily Living (MG-ADL) or Quantitative MG (QMG) score change from baseline. RESULTS: Of 4,823 eligible studies, 27 placebo-controlled randomized trials (placebo n = 1,086; treatment n = 1,232) were included that targeted B cells, neonatal Fc receptor (FcRn), complement activity, CD40, and interleukin-6 signaling, as well as immunoglobulin G and broad immunosuppression therapy. Compared to those treated with placebo and standard of care, QMG scores decreased by an average of -3.63 (95% credible interval -4.43 to -2.77) points more in patients treated with FcRn inhibitors, -2.59 (-3.92 to -1.28) points more in patients treated with C5 complement inhibitors (C5i), and -2.50 (-5.11 to 0.12) points more in patients treated with CD19+ B-cell depletion therapy (BCDT). The MG-ADL treatment effects were -1.93 (-2.21 to -1.65) for FcRn inhibitors, -1.84 (-2.48 to -1.19) for C5i, and -1.91 (-2.97 to -0.84) for CD19+ BCDT. Sensitivity analyses detected potential confounding of treatment effects by age and sex. Patients treated with FcRn inhibitors had greater odds of treatment-related adverse events (odds ratio 2.20 [1.52-3.38]) compared with the placebo group, while C5i and CD19+ BCDT showed odds comparable to placebo. DISCUSSION: FcRn inhibitors, C5i, and CD19+ BCDT showed comparable efficacy in terms of QMG and MG-ADL reduction because meaningful differences were not observed between treatment classes. Our findings also highlight how differences between trial populations may confound the interpretation of study outcomes. Prospective comparative efficacy studies are warranted.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. McLaren NP, Rosati M, Zhong W, et al. Comparison of the Efficacy and Safety of Myasthenia Gravis Treatments: A Bayesian Network Meta-Analysis. Neurology. 2026. PMID: 42467874. doi:10.1212/WNL.0000000000218351

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。